Compare Inovio Pharmaceuticals Inc (INO) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Noble Corporation plc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Noble Corporation plc trades at $41.66 (market cap $6.48B). The key difference: Noble Corporation plc is far larger — about 72.6× Inovio Pharmaceuticals Inc's market cap, and Noble Corporation plc pays a 4.93% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NE | |
|---|---|---|
Market Cap | $89.27M | $6.48B |
Sector | Health | Technology |
52-Week High | $2.87 | $54.37 |
52-Week Low | $1.05 | $25.70 |
Enterprise Value | $60.28M | $7.73B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Noble Corporation (NE) trades at $40.60, down 2.17% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators. The company maintains solid fundamentals with a $3.29B revenue in 2025 and a net income margin of 7.17%, supported by recent contract wins like the $136.2M Brunei drilling deal. Cash flow remains positive, and a $0.50 dividend was recently declared, payable in June 2026.
The outlook is cautiously optimistic with a consensus price target of $49.75 offering 22.5% upside, though recent earnings misses and competitive pressures in offshore drilling pose risks. Analyst sentiment is divided with 31% buy ratings, reflecting confidence in Noble's high-specification rig fleet and contract backlog, balanced by execution challenges and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
